

Publisher: John Wiley & Sons Inc
E-ISSN: 1467-9876|64|3|507-523
ISSN: 0035-9254
Source: JOURNAL OF THE ROYAL STATISTICAL SOCIETY: SERIES C (APPLIED STATISTICS), Vol.64, Iss.3, 2015-04, pp. : 507-523
Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.
Abstract
Related content


A Bayesian dose‐finding design for phase I/II clinical trials with nonignorable dropouts
STATISTICS IN MEDICINE, Vol. 34, Iss. 10, 2015-05 ,pp. :





